Another potential set of targets that may be successfully targeted in KRAS mutant NSCLC are the cyclin-dependent kinases (CDKs) which are critical regulatory enzymes that drive the cell cycle. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.